Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) Cash & Current Investments (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed Cash & Current Investments for 6 consecutive years, with $13.4 million as the latest value for Q3 2018.

  • Quarterly Cash & Current Investments rose 73.37% to $13.4 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $13.4 million through Sep 2018, up 73.37% year-over-year, with the annual reading at $5.1 million for FY2017, 0.0% changed from the prior year.
  • Cash & Current Investments hit $13.4 million in Q3 2018 for Armata Pharmaceuticals, down from $15.4 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $16.6 million in Q1 2015 to a low of $2.2 million in Q1 2017.
  • Historically, Cash & Current Investments has averaged $9.5 million across 5 years, with a median of $9.0 million in 2017.
  • Biggest YoY gain for Cash & Current Investments was 2185.81% in 2014; the steepest drop was 67.67% in 2014.
  • Year by year, Cash & Current Investments stood at $6.6 million in 2014, then soared by 42.38% to $9.4 million in 2015, then plummeted by 45.23% to $5.1 million in 2016, then changed by 0.0% to $5.1 million in 2017, then soared by 160.97% to $13.4 million in 2018.
  • Business Quant data shows Cash & Current Investments for ARMP at $13.4 million in Q3 2018, $15.4 million in Q2 2018, and $8.2 million in Q1 2018.